BioCentury
ARTICLE | Clinical News

Oral CR845: Phase I started

July 14, 2014 7:00 AM UTC

Cara began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate up to 6 dose levels of oral CR845 in up to 150 healthy volunteers. Oral CR845 contains a peptide formulation technology fr...